sj-pptx-1-taj-10.1177_20406223231223286 – Supplemental material for The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira

McClellan, Joseph E.; Ómarsdóttir, Sesselja; Roy, Nivedita; Berger, Verena; Michel, Cecilia; Berti, Fausto

doi:10.25384/SAGE.25034893.v2

sj-pptx-1-taj-10.1177_20406223231223286.pptx (38.76 MB)

sj-pptx-1-taj-10.1177_20406223231223286 – Supplemental material for The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira

Version 2 2024-04-10, 12:07

Version 1 2024-01-20, 13:08

presentation

posted on 2024-04-10, 12:07 authored by Joseph E. McClellan, Sesselja Ómarsdóttir, Nivedita Roy, Verena Berger, Cecilia Michel, Fausto Berti

Supplemental material, sj-pptx-1-taj-10.1177_20406223231223286 for The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira by Joseph E. McClellan, Sesselja Ómarsdóttir, Nivedita Roy, Verena Berger, Cecilia Michel and Fausto Berti in Therapeutic Advances in Chronic Disease